Columns

Nonprofits around the world are hoping to “turn up the global volume” for Huntington’s Disease Awareness Month, an annual event in May to call attention to the disease, estimated to affect up to 7 per 100,000 people globally. In the U.S., about 41,000 Americans are affected by the disease,…

The Phase 3 PROOF-HD trial failed to meet its main goal of showing that pridopidine, Prilenia Therapeutics’ experimental therapy, could slow functional decline compared with a placebo for adults with Huntington’s disease. However, preliminary top-line data indicated a potential slowing of disease progression among patients who were…

Asklepios Biopharmaceutical (AskBio) has launched a first-in-human clinical trial testing AB-1001 — an experimental gene therapy designed to modulate cholesterol metabolism in the brain — in people with Huntington’s disease. The trial is currently recruiting participants at a site in Paris. It is open to adults, ages 18…

An encouraging number of clinical trials are currently recruiting, or soon will be, for people affected by Huntington’s disease (HD). I recently wrote about the CAP score, a mathematical calculation that many HD clinical studies use to find participants who are at comparable points along their HD…

In 2018, my wife, Jill, was diagnosed as gene-positive for Huntington’s disease (HD). In the months leading up to her diagnosis, she’d begun experiencing depression and anxiety, as well as other HD symptoms, which started her down the long road of finding helpful medications. At…

Subtle changes in speech are present before obvious symptoms of Huntington’s disease appear, and could potentially be a quantitative biomarker for the neurodegenerative disorder, a small study found. The changes in speaking identified among Huntington’s patients were linked to age and an individual’s number of disease-causing CAG repeats —…

In a recent column, I shared that I was battling a serious infection, which led to a four-day hospital stay. My main concern was about my wife, Jill, who is gene-positive for Huntington’s disease (HD), and how frustrating it was for me to be sick when it’s…

A Phase 1/2a clinical trial testing VO659, Vico Therapeutics’ experimental therapy, in people with Huntington’s disease and other hereditary neurological disorders caused by a similar type of mutation has dosed the first patient. “We are encouraged by the continued progress of our development program and very pleased to…

“Do you ever feel like Huntington’s disease [HD] is the villain in the movie of our lives?” my wife, Jill, asked me recently. My wife and I live in a neighborhood with many trees and little light. As I arrived home after work one day last month, darkness greeted…